Schizophrenia News and Research

Latest Schizophrenia News and Research

Cortex second quarter net loss decreases to $356,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.

18 Aug 2011

Researchers to unravel how brain makes everyday prognostications

Every day we make thousands of tiny predictions - when the bus will arrive, who is knocking on the door, whether the dropped glass will break. Now, in one of the first studies of its kind, researchers at Washington University in St. Louis are beginning to unravel the process by which the brain makes these everyday prognostications.

18 Aug 2011

Mice with enzyme deficiency are unable to properly assess threat

Do you run when you should stay? Are you afraid of all the wrong things? An enzyme deficiency might be to blame, reveals new research in mice by scientists at the University of Southern California.

12 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

Women with depression at higher risk of stroke

A new study published this week shows that depression puts middle-aged and older women at significant risk of suffering potentially debilitating strokes.

12 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

Study suggests ways to remediate cognitive errors

Concern about the capacity of individuals with schizophrenia to consent to clinical research studies has largely focused on impairment due to psychotic symptoms associated with the disorder. Less attention has been given to the cognitive errors that prospective participants make when undergoing a formal assessment of decisional capacity.

10 Aug 2011

Schizophrenia not always inherited – Genetic links found

Researchers have found that more than half the cases of non-hereditary or sporadic schizophrenia are caused by “new” protein-altering gene mutations. These mutations are new genetic errors that appear in patients but not in either of their parents, the researchers explained in the report published in the Aug. 7 online edition of the journal Nature Genetics.

8 Aug 2011

De novo mutations account for 50% of sporadic cases of schizophrenia

Columbia University Medical Center researchers have shown that new, or "de novo," protein-altering mutations—genetic errors that are present in patients but not in their parents—play a role in more than 50 percent of "sporadic" —i.e., not hereditary—cases of schizophrenia.

8 Aug 2011

Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.

5 Aug 2011

Longer looks: Treating Down syndrome?; mentally ill, meds & trials

Politicians want to lower spending, or at least they say they do. But in all the to-and-fro over raising the debt ceiling, little sensible has been said about lowering spending in the long term. Nothing illuminates this more clearly than health care.

5 Aug 2011

Risperidone does not appear to reduce military-related PTSD symptoms

Patients with military-related, chronic posttraumatic stress disorder (PTSD) and symptoms that were not improved with use of an antidepressant medication did not experience a reduction in PTSD symptoms with use of the antipsychotic medication risperidone, according to a study in the August 3 issue of JAMA, a theme issue on violence and human rights.

3 Aug 2011

Post-traumatic stress disorder drug risperidone not working: Study

According to a new study a medication commonly used to treat post-traumatic stress disorder in combat veterans may not be effective in reducing overall PTSD severity.

3 Aug 2011

Brain stimulation improves learning in people with schizophrenia

Very mild electrical brain stimulation could be used as a treatment for people with schizophrenia, say researchers.

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

EMA accepts to evaluate Vanda's MAA for oral iloperidone tablets

Vanda Pharmaceuticals Inc. announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets.

27 Jul 2011

NeurOp receives NIH grant to support research program for ischemia

NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support its research program for ischemia.

27 Jul 2011

Drugs targeting specific brain region could help people with schizophrenia manage daily life, study shows

A new study has identified the neural mechanism that hinders reward identification and decision-making in people suffering from schizophrenia, highlighting the need for more effective drug therapies to help people with the disease manage their daily lives.

25 Jul 2011

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.

22 Jul 2011

State news: Florida effort could cost consumers $60 million in rebates

The JMH Health Plan, the insurance wing of the Jackson Health System, has become a huge money-loser that must be fixed quickly, board members were told Thursday. So far this year, the plan has lost $30.4 million — almost half of the $71.7 million that Jackson Health System has lost for the entire fiscal year.

22 Jul 2011